Front Row Advisors’s Medtronic MDT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.5K | Hold |
200
| – | – | 0.01% | 328 |
|
|
2025
Q4 | $19.4K | Hold |
200
| – | – | 0.01% | 316 |
|
|
2025
Q3 | $19.2K | Hold |
200
| – | – | 0.01% | 313 |
|
|
2025
Q2 | $17.6K | Hold |
200
| – | – | 0.01% | 311 |
|
|
2025
Q1 | $18.1K | Hold |
200
| – | – | 0.01% | 303 |
|
|
2024
Q4 | $16K | Hold |
200
| – | – | 0.01% | 319 |
|
|
2024
Q3 | $18.1K | Sell |
200
-557
| -74% | -$46.9K | 0.01% | 305 |
|
|
2024
Q2 | $60.1K | Hold |
757
| – | – | 0.02% | 248 |
|
|
2024
Q1 | $66.5K | Buy |
757
+557
| +279% | +$47.5K | 0.02% | 228 |
|
|
2023
Q4 | $16.6K | Sell |
200
-557
| -74% | -$42.5K | 0.01% | 274 |
|
|
2023
Q3 | $60.1K | Sell |
757
-388
| -34% | -$32.5K | 0.03% | 215 |
|
|
2023
Q2 | $102K | Sell |
1,145
-9,490
| -89% | -$817K | 0.05% | 171 |
|
|
2023
Q1 | $865K | Sell |
10,635
-704
| -6% | -$57.4K | 0.41% | 59 |
|
|
2022
Q4 | $889K | Sell |
11,339
-12,860
| -53% | -$1.04M | 0.46% | 60 |
|
|
2022
Q3 | $1.97M | Sell |
24,199
-572
| -2% | -$51.4K | 1.02% | 25 |
|
|
2022
Q2 | $2.24M | Sell |
24,771
-20
| -0.1% | -$2.03K | 1.1% | 24 |
|
|
2022
Q1 | $2.77M | Buy |
24,791
+3
| +0% | +$317 | 1.12% | 22 |
|
|
2021
Q4 | $2.58M | Sell |
24,788
-325
| -1% | -$37.6K | 0.96% | 29 |
|
|
2021
Q3 | $3.16M | Sell |
25,113
-110
| -0.4% | -$14.2K | 1.34% | 14 |
|
|
2021
Q2 | $3.25M | Sell |
25,223
-479
| -2% | -$60.1K | 1.33% | 14 |
|
|
2021
Q1 | $3.05M | Buy |
25,702
+264
| +1% | +$30.9K | 1.48% | 10 |
|
|
2020
Q4 | $3M | Sell |
25,438
-885
| -3% | -$97.4K | 1.53% | 8 |
|
|
2020
Q3 | $3.02M | Sell |
26,323
-504
| -2% | -$50.6K | 1.6% | 6 |
|
|
2020
Q2 | $2.48M | Sell |
26,827
-245
| -0.9% | -$23.5K | 1.54% | 9 |
|
|
2020
Q1 | $2.64M | Buy |
27,072
+452
| +2% | +$48.1K | 1.79% | 5 |
|
|
2019
Q4 | $3.03M | Sell |
26,620
-237
| -0.9% | -$26K | 1.98% | 4 |
|
|
2019
Q3 | $2.93M | Buy |
26,857
+41
| +0.2% | +$4.28K | 2.09% | 4 |
|
|
2019
Q2 | $2.61M | Buy |
26,816
+26,110
| +3,698% | +$2.38M | 1.9% | 5 |
|
|
2019
Q1 | $65K | Buy |
706
+3
| +0.4% | +$269 | 0.05% | 180 |
|
|
2018
Q4 | $64K | Buy |
703
+35
| +5% | +$3.27K | 0.06% | 174 |
|
|
2018
Q3 | $61 | Buy |
668
+40
| +6% | +$3.7K | 0.04% | 187 |
|
|
2018
Q2 | $56 | Buy |
628
+19
| +3% | +$1.59K | 0.04% | 204 |
|
|
2018
Q1 | $49K | Hold |
609
| – | – | 0.03% | 223 |
|
|
2017
Q4 | $49K | Buy |
+609
| New | +$48.8K | 0.04% | 227 |
|
Other funds holding MDT
VCM
VPM
Front Row Advisors's MDT Position: Q1 2026 in Review
Front Row Advisors held its Medtronic (MDT) position steady in Q1 2026 at 200 shares worth $17.5K. The position accounts for 0.01% of the portfolio, ranked #328.
Front Row Advisors first reported a position in MDT in Q4 2017 and has held it in 34 quarters since. The position peaked at $3.25M in Q2 2021. 2,229 funds tracked by Wall St. Rank hold MDT as of Q1 2026.
- Front Row Advisors held 200 shares of Medtronic worth $17.5K as of Q1 2026.
- Front Row Advisors left its Medtronic share count unchanged in Q1 2026.
- Medtronic made up 0.01% of Front Row Advisors's portfolio in Q1 2026, its #328 holding.
- Front Row Advisors first reported a position in Medtronic in Q4 2017 and has held it in 34 quarters since.
- Front Row Advisors's Medtronic position peaked at $3.25M in Q2 2021.
- 2,229 funds tracked by Wall St. Rank held Medtronic as of Q1 2026.
Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.